Astria Therapeutics (NASDAQ:ATXS) Price Target Lowered to $16.00 at HC Wainwright

Astria Therapeutics (NASDAQ:ATXS) had its target price reduced by HC Wainwright from $18.00 to $16.00 in a report published on Tuesday morning, Benzinga reports. They currently have a buy rating on the biotechnology company’s stock.

Other analysts also recently issued reports about the company. Wedbush reiterated an outperform rating and set a $17.00 target price on shares of Astria Therapeutics in a research report on Tuesday, March 26th. Jefferies Financial Group boosted their price target on Astria Therapeutics from $22.00 to $27.00 and gave the stock a buy rating in a report on Monday, March 25th.

Astria Therapeutics Stock Performance

ATXS opened at $9.64 on Tuesday. The business’s fifty day moving average is $13.31 and its two-hundred day moving average is $9.27. The company has a market cap of $529.24 million, a price-to-earnings ratio of -4.12 and a beta of 0.69. Astria Therapeutics has a one year low of $4.26 and a one year high of $16.90.

Astria Therapeutics (NASDAQ:ATXS) last posted its earnings results on Monday, March 4th. The biotechnology company reported ($0.86) EPS for the quarter, missing analysts’ consensus estimates of ($0.78) by ($0.08). On average, analysts predict that Astria Therapeutics will post -1.55 EPS for the current fiscal year.

Insider Transactions at Astria Therapeutics

In related news, Director Perceptive Advisors Llc purchased 2,481,350 shares of the business’s stock in a transaction dated Thursday, February 1st. The stock was bought at an average cost of $12.09 per share, with a total value of $29,999,521.50. Following the completion of the acquisition, the director now directly owns 4,873,721 shares in the company, valued at approximately $58,923,286.89. The acquisition was disclosed in a document filed with the SEC, which can be accessed through the SEC website. In related news, insider Christopher Morabito sold 9,200 shares of the company’s stock in a transaction on Monday, January 29th. The stock was sold at an average price of $11.15, for a total value of $102,580.00. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Perceptive Advisors Llc bought 2,481,350 shares of the company’s stock in a transaction that occurred on Thursday, February 1st. The stock was acquired at an average price of $12.09 per share, with a total value of $29,999,521.50. Following the completion of the purchase, the director now directly owns 4,873,721 shares of the company’s stock, valued at approximately $58,923,286.89. The disclosure for this purchase can be found here. Insiders own 3.40% of the company’s stock.

Hedge Funds Weigh In On Astria Therapeutics

Several institutional investors have recently added to or reduced their stakes in the business. AJOVista LLC acquired a new position in Astria Therapeutics in the fourth quarter valued at $51,000. Jump Financial LLC acquired a new stake in Astria Therapeutics during the third quarter worth about $111,000. Panagora Asset Management Inc. acquired a new stake in Astria Therapeutics during the fourth quarter worth about $119,000. Trexquant Investment LP acquired a new stake in Astria Therapeutics during the fourth quarter worth about $409,000. Finally, ADAR1 Capital Management LLC acquired a new stake in Astria Therapeutics during the fourth quarter worth about $1,469,000. 98.98% of the stock is currently owned by institutional investors and hedge funds.

Astria Therapeutics Company Profile

Astria Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for allergic and immunological diseases in the United States. Its lead product candidate is STAR-0215, a monoclonal antibody inhibitor of plasma kallikrein, which is in Phase 1b/2 clinical trials for the treatment of hereditary angioedema.